Drug Trial Radar · NCT00488631
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Apr 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,228
Actual
Start
Sep 2007
Primary completion
Oct 2011
Study completion Feb 2015
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 20, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.
Conditions
- Colitis, Ulcerative
Interventions
PlaceboBiological
Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
Golimumab 50 mgBiological
Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
Golimumab 100 mgBiological
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
Golimumab 200 mgBiological
Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants in Clinical Response Through Week 54Time frame: Induction Baseline, Week 0 through Week 54
Locations
297 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Merced, California
Site not named
Orange, California
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
Lakewood, Colorado
Site not named
Littleton, Colorado
Site not named
Bristol, Connecticut
Site not named
Newark, Delaware
Site not named
Boca Raton, Florida
Site not named
Gainesville, Florida
Site not named
Hialeah, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Naples, Florida
Site not named
New Port Richey, Florida
Site not named
North Miami Beach, Florida
Site not named
Port Orange, Florida
Site not named
Tampa, Florida
Site not named
Winter Park, Florida
Site not named
Zephyrhills, Florida
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Savannah, Georgia
Site not named
Snellville, Georgia
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Clive, Iowa
Site not named
Fort Dodge, Iowa
Site not named
Pratt, Kansas
Site not named
Topeka, Kansas
Site not named
Lexington, Kentucky
Site not named
Louisville, Kentucky
Site not named
Monroe, Louisiana
Site not named
Hagerstown, Maryland
Site not named
Hollywood, Maryland
Site not named
Laurel, Maryland
Site not named
Worcester, Massachusetts
Showing 40 of 297 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.